262,885 Shares in Tandem Diabetes Care, Inc. $TNDM Acquired by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC bought a new stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 262,885 shares of the medical device company’s stock, valued at approximately $5,778,000. Tandem Diabetes Care makes up 1.4% of Lisanti Capital Growth LLC’s investment portfolio, making the stock its 20th biggest holding. Lisanti Capital Growth LLC owned 0.39% of Tandem Diabetes Care as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of TNDM. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Tandem Diabetes Care by 200.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,205 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 1,470 shares in the last quarter. Quarry LP boosted its holdings in shares of Tandem Diabetes Care by 2,597.1% in the 3rd quarter. Quarry LP now owns 3,695 shares of the medical device company’s stock valued at $45,000 after purchasing an additional 3,558 shares in the last quarter. Aster Capital Management DIFC Ltd boosted its holdings in shares of Tandem Diabetes Care by 485.1% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 5,149 shares of the medical device company’s stock valued at $63,000 after purchasing an additional 4,269 shares in the last quarter. Creative Financial Designs Inc. ADV boosted its holdings in shares of Tandem Diabetes Care by 36.0% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 3,431 shares of the medical device company’s stock valued at $75,000 after purchasing an additional 909 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Tandem Diabetes Care by 36.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,600 shares of the medical device company’s stock valued at $79,000 after purchasing an additional 965 shares in the last quarter.

Wall Street Analysts Forecast Growth

TNDM has been the topic of a number of research analyst reports. Stifel Nicolaus raised their target price on Tandem Diabetes Care from $20.00 to $22.00 and gave the company a “hold” rating in a report on Friday, February 20th. Barclays set a $55.00 target price on Tandem Diabetes Care and gave the company an “overweight” rating in a report on Monday, May 11th. Lake Street Capital raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $50.00 target price on the stock in a report on Monday, February 23rd. The Goldman Sachs Group reduced their target price on Tandem Diabetes Care from $28.00 to $25.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Finally, Benchmark initiated coverage on Tandem Diabetes Care in a report on Monday, May 11th. They issued a “hold” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.63.

Tandem Diabetes Care Stock Down 5.0%

Shares of TNDM opened at $14.97 on Friday. Tandem Diabetes Care, Inc. has a 52 week low of $9.98 and a 52 week high of $29.65. The stock has a market capitalization of $1.03 billion, a price-to-earnings ratio of -10.69 and a beta of 1.64. The company has a debt-to-equity ratio of 4.54, a quick ratio of 3.07 and a current ratio of 3.58. The stock has a fifty day moving average of $19.34 and a 200-day moving average of $20.26.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its earnings results on Thursday, May 7th. The medical device company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.16. The business had revenue of $247.22 million during the quarter, compared to analyst estimates of $240.41 million. Tandem Diabetes Care had a negative return on equity of 53.88% and a negative net margin of 9.20%.Tandem Diabetes Care’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period last year, the company earned ($0.66) EPS. As a group, sell-side analysts anticipate that Tandem Diabetes Care, Inc. will post -0.79 earnings per share for the current fiscal year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.